Quote | Purple Biotech Ltd ADR (Sponsored) Level 3 (NASDAQ:PPBT)
Last: | $0.53 |
---|---|
Change Percent: | -4.25% |
Open: | $0.564 |
Close: | $0.53 |
High: | $0.57 |
Low: | $0.53 |
Volume: | 103,438 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
News | Purple Biotech Ltd ADR (Sponsored) Level 3 (NASDAQ:PPBT)
Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stag...
NT219 found to suppress cancer stem cells that promote drug resistance to KRAS G12C and KRAS G12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in responding patients in Phase 1 REHOVOT, Israel, March 28, 2024 (G...
Message Board Posts | Purple Biotech Ltd ADR (Sponsored) Level 3 (NASDAQ:PPBT)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $KTOV News Article - New Mechanism of Action Data for NT219 Presented at Epigenetics an | whytestocks | investorshangout | 10/16/2020 4:35:45 PM |
whytestocks: $KTOV News Article - Kitov Pharma Receives Notice of Intention to Grant Two Patents in | whytestocks | investorshangout | 09/04/2020 7:30:46 PM |
znewcar1: KTOV 837% v1,5M c4.77 f17,2M RS | znewcar1 | investorshangout | 08/21/2020 8:07:55 PM |
whytestocks: $KTOV News Article - Kitov Announces Initiation of Phase 1/2 Clinical Trial of NT219 in | whytestocks | investorshangout | 07/09/2020 12:15:48 PM |
znewcar1: KTOV 46% v219M c1.26 f118M H1.4 S1.07 | znewcar1 | investorshangout | 06/25/2020 9:39:00 PM |
News, Short Squeeze, Breakout and More Instantly...
Purple Biotech Ltd ADR (Sponsored) Level 3 Company Name:
PPBT Stock Symbol:
NASDAQ Market:
Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stag...
NT219 found to suppress cancer stem cells that promote drug resistance to KRAS G12C and KRAS G12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in responding patients in Phase 1 REHOVOT, Israel, March 28, 2024 (G...
Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the local tumor micro environment which increases the anticipated therapeutic window in patients REHOVOT, Israel, March 14, 2024...